Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.

Also called NCT02396758

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 131 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02396758
  • EudraCT 2016-000502-11
Other papers using this trial's data
  • A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial JACC. Cardiovascular interventions, 2018-07-23 DOI, PubMed 30025734

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02396758. Randomized; no masking; primary purpose treatment. Start 2015-06-12 (actual); primary completion 2019-04-30 (actual). Results posted on 2021-03-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
Acronym
OPTALYSE PE
Condition
Pulmonary Embolism and Thrombosis
Intervention (Device)
Ekosonic® Endovascular Device ultrasonic infusion catheter
Intervention (Biological)
Recombinant tissue plasminogen activator
Lead sponsor
Boston Scientific Corporation (class: industry)
Collaborator
EKOS Corporation (class: industry)

Record details

Record id
cardio:ct-nct02396758
Content hash
97065ac93ca1f0afa9dc3e6b6830877e6192b117058004a55ba7c14071d31d7c